Long Term Changes ACS Revascularization

Long term outcomes support complete revascularization in multivessel patients undergoing acute coronary syndrome (ACS).

infarto peri-procedimiento

This large contemporary registry recently published in J Am Coll Cardiol Intv.  has shown complete revascularization is gaining ground in the daily practice and is associated to clinical benefits in patients undergoing ACS. 

It included 9094 individuals with ACS and multivessel disease (>70% stenosis in 2 or more epicardial vessels) receiving PCI.

It looked at the link between complete revascularization and all cause death and repeat MI vs. incomplete revascularization.

66% of all patients received complete revascularization. These were compared against the remaining 34%.


Read also: Rapid Drop of Antibodies in Mild COVID-19 patients.


Primary end point at 5 years was frequent in those undergoing complete revascularization (15.4% vs. 22.2%; HR: 0.78; CI 95%:0.73 to 0.84; p<0.0001).

Repeat revascularization combined with all cause death and infarction was among the secondary end points and also resulted better with complete revascularization (23.3% vs. 37.5%; HR: 0.61; CI 95%: 0.58 to 0.65; p<0.0001).

Each of the above mentioned points were looked at separately and also resulted significantly superior with complete revascularization: all cause death (HR: 0.79; CI 95%: 0.73 to 0.86; p=0.0004), repeat MI (HR: 0.76; CI 95%: 0.69 to 0.84; p<0.0001) and repeat revascularization (HR: 0.53; CI 95%: 0.49 to 0.57; p<0.0001).

Conclusion

The 5-year outcomes of this large contemporary registry of ACS patients with multivessel disease suggest complete revascularization is habitual in the daily clinical practice and is associated with significant benefits as regards the main clinical end points. 

Original Title: Long-Term Outcomes of Complete Revascularization With Percutaneous Coronary Intervention in Acute Coronary Syndromes.

Reference: Kevin R. Bainey et al. J Am Coll Cardiol Intv 2020;13:1557–67. https://doi.org/10.1016/j.jcin.2020.04.034.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...